Kymera Therapeutics, Inc. (KYMR) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
KYMR EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
KYMR Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 100.0% | -891.3% | -794.4% |
| 2024 | 100.0% | -555.8% | -475.6% |
| 2023 | 100.0% | -210.6% | -187.0% |
| 2022 | 100.0% | -344.4% | -330.6% |
| 2021 | 100.0% | -138.0% | -137.6% |
Download Data
Export KYMR earnings history in CSV or JSON format
Free sign-in required to download data
Kymera Therapeutics, Inc. (KYMR) Earnings Overview
As of May 7, 2026, Kymera Therapeutics, Inc. (KYMR) reported trailing twelve-month net income of -$315M, reflecting -23.8% year-over-year growth. The company earned $-3.23 per diluted share over the past four quarters, with a net profit margin of -794.4%.
Looking at the long-term picture, KYMR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$21M in fiscal 2018.
Kymera Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARVN (-$81M net income, -30.8% margin), PRAX (-$303M net income), VKTX (-$472M net income), KYMR has room to improve margins relative to the peer group. Compare KYMR vs ARVN →
KYMR Earnings vs Peers
Earnings metrics vs comparable public companies
KYMR Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$311M | -39.1% | -$349M | $-3.69 | -794.4% | -891.3% |
| 2024 | -$224M | -52.3% | -$262M | $-2.98 | -475.6% | -555.8% |
| 2023 | -$147M | +5.1% | -$166M | $-2.52 | -187.0% | -210.6% |
| 2022 | -$155M | -54.5% | -$161M | $-2.87 | -330.6% | -344.4% |
| 2021 | -$100M | -119.8% | -$101M | $-2.09 | -137.6% | -138.0% |
| 2020 | -$46M | -10.4% | -$46M | $-0.99 | -134.0% | -136.1% |
| 2019 | -$41M | -92.4% | -$42M | $-0.93 | -1407.4% | -1438.5% |
| 2018 | -$21M | - | -$21M | $-0.48 | - | - |
See KYMR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KYMR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KYMR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKYMR — Frequently Asked Questions
Quick answers to the most common questions about buying KYMR stock.
Is KYMR growing earnings?
KYMR EPS fell to $-3.23, with earnings declining -23.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-315M.
What are KYMR's profit margins?
Kymera Therapeutics, Inc. net margin is -794.4%, with operating margin at -891.3%. Below-average margins reflect competitive or cost pressures.
How consistent are KYMR's earnings?
KYMR earnings data spans 2018-2025. The declining earnings trend is -23.8% YoY. Historical data enables comparison across business cycles.